Abstract: The present invention relates to novel Histone Deacetylase Inhibitors (HDACi)-based antibody drug conjugates particularly with antibodies directed to ErbB, ErbB2 and ErbB3 receptors, pharmaceutical compositions comprising said antibodies as well as to their use in the treatment of cancer or tumor and other diseases where a modulation of one or more histone deacetylase isoforms can be effective for therapeutic interventions.

Abstract: A pharmaceutical composition comprising (i) an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents a connecting position to an antibody) is conjugated to the antibody via a thioether bond, (ii) a histidine buffer, (iii) sucrose or trehalose, and (iv) a surfactant; and a method of lyophilizing the pharmaceutical composition.

Abstract: The invention provides murine, chimeric, and humanized antibodies that specifically bind to CD123 and conjugates thereof.

Abstract: The present invention relates to a method for generating an antibody-payload conjugate by means of a microbial transglutaminase (MTG). The method comprises a step of conjugating a linker having a primary amine residue, said linker having the peptide structure (shown in N->C direction) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, or (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, to a Gln residue comprised in the heavy or light chain of an antibody. Aax(NH2) is an amino acid, amino acid derivative or amino acid mimetic comprising a side chain having a primary amine group.

Abstract: The invention provides immunoconjugates of Formula I comprising an antibody linked by conjugation to one or more thienoazepine derivatives. The invention also provides thienoazepine derivative intermediate compositions comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the immunoconjugates through a linker or linking moiety. The invention further provides methods of treating cancer with the immunoconjugates.

Abstract: Disclosed are a peptide capable of induced self-assembly by a bioactive molecule comprising a (i) hydrogelation-promoting amino acid sequence and (ii) an oligomerization sequence; compositions containing the peptide and, optionally, bioactive molecule; hydrogels formed thereby; and various methods of using the same

Abstract: The present invention discloses a multifunctional DNA-templated micelle system that has a payload carrier of at least a DNA bridge and a functionalized polyethylene glycol (PEG) segment. The micelle can be used to deliver molecules, such as drugs and polynucleotides, to targeted cells for pharmaceutical uses. The PEG segment provides a functional group, such as amine, for ligand conjugation. The DNA-templated micelle of the present invention is highly controllable in size, loading efficiency and tissue targeting, and can carry multiple payloads for targeted combination strategies in cancer therapy, such as gene delivery, gene therapy, and immunotherapy.

Abstract: A cell-penetrating peptide (CPP) comprising comprises a plurality of mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s where a plurality of the amino acids comprise a positively charged guanylurea unit with a small molecule fragment and each of the mono(amino acid)s, oligo(amino acid)s, or poly(amino acid)s comprising a drug attached through a linker. The CPP can be used for treating cancers.

Abstract: The present invention relates to three-dimensional self-assembled nucleic acid nanoparticles, a drug delivery system comprising the same, and a pharmaceutical composition for the prevention or treatment of acute kidney injury, which comprises the same. The three-dimensional self-assembled nucleic acid nanoparticles of the present invention, which have a tetrahedral structure, exhibit an excellent renal-targeting ability, and thus the nanoparticles conjugated with the pharmaceutically active ingredient for p53 exhibit excellent p53 and caspase 3 expression reductions in vitro and in vivo, and can thereby be applied to the prevention or treatment of acute kidney injury.

Abstract: The invention provides gene therapy vectors, such as adeno-associated vims (AAV) vectors, expressing a miniaturized human micro-dystrophin gene and method of using these vectors to express micro-dystrophin in skeletal muscle including diaphragm and cardiac muscle and to protect muscle fibers from injury, increase muscle strength and reduce and/or prevent fibrosis in subjects suffering from muscular dystrophy.

Abstract: Provided herein are compositions and methods for the design of synthetic regulatory sequences and for subsequent modulation of neural pathways.

Abstract: Disclosed herein are recombinant viral vectors comprising a liver specific promotor in operable combination with a heterologous nucleic acid sequence encoding a protein, such as a clotting factor. Methods of treating a subject with a clotting disorder, such as hemophilia A or hemophilia B, are also provided.

Abstract: The present invention relates to a method for culturing a 3-dimensional lung cancer organoid and a method for preparing a patient-derived xenograft animal model using the same. More specifically, the present invention relates to a method for culturing a 3-dimensional lung cancer organoid, a lung cancer organoid prepared by the method, a medium composition for culturing the lung cancer organoid, a method for preparing a xenograft animal model using the lung cancer organoid, a patient-derived lung cancer organoid xenograft animal model prepared by the method, and a method for analyzing therapeutic efficacy of an anticancer agent and a method for screening an anticancer agent, using the animal model.

Abstract: Activity-based probe compounds for use in labeling a cysteine protease are provided. The compounds are targeted to the protease through a specific targeting element. The compounds additionally include a detectable element, such as a fluorescent label, a radiolabel, or a chelator. In some cases, the compounds additionally include a quenching element that is released upon reaction with the protease. Also provided are compositions comprising the compounds and methods for using the compounds, for example in labeling a protease in an animal and in visualizing a tumor in an animal.

Abstract: The present invention relates to a method of necrosing, causing membranolysis, or causing poration of selective cancer cells. In some aspects, the method includes administering a peptide including PPLSQETFSDLWKLL-KKWKMRRN QFW VKV QRG or ETFSDLWKLL-KKWKMRRNQFWVKVQRG to a selective cancer cell to cause necrosis, membranolysis, or poration of said selective cancer cell.

Abstract: Methods and compositions for detecting tau pathology are described. The compositions for detecting tau pathology comprise a targeting ligand that specifically binds to a cell surface marker of tau pathology, wherein the targeting ligand is linked to a liposome that includes an imaging agent. The compositions can be used in a method for imaging tau pathology in a subject that comprises administering to the subject an effective amount of the composition to a subject and imaging at least a portion of the subject to determine if that portion of the subject exhibits tau pathology. The compositions can also be used to detect tau pathology in biological samples obtained from a subject.

Abstract: A radioligand for labeling myelin includes a fluorescent trans-stilbene derivative.

Abstract: The present technology provides compounds, as well as compositions including such compounds, useful for imaging and/or treatment of a glioma, a breast cancer, an adrenal cortical cancer, a cervical carcinoma, a vulvar carcinoma, an endometrial carcinoma, a primary ovarian carcinoma, a metastatic ovarian carcinoma, a non-small cell lung cancer, a small cell lung cancer, a bladder cancer, a colon cancer, a primary, gastric adenocarcinoma, a primary colorectal adenocarcinoma, a renal cell carcinoma, and/or a prostate cancer. The compounds are represented by the following formula: (I) or a pharmaceutically acceptable salt thereof.

Abstract: The present invention relates to a somatostatin analogue composition for radiopharmaceutical use, in particular for diagnostic or therapeutic use. More specifically the somatostatin analogue is a receptor-selective somatostatin peptide antagonist.

Abstract: A decontamination device (1) for decontaminating products in the form of consumer goods and/or consumer good packaging having consumer goods located therein prior to supplying the consumer goods into an isolator, the decontamination device comprising several decontamination chambers (3, 4, 5, 6) each having a closable inlet opening (9) and a closable outlet opening (10), and each comprising application means (7) for applying a decontamination agent, to the decontamination chambers (3, 4, 5, 6), and the decontamination device (1) comprising a distributor chamber (11) disposed upstream of the decontamination chambers (3, 4, 5, 6) and having a supply opening (24) for products to be decontaminated, the distributor chamber (11) comprising distributor means (15) for distributing the products to the different decontamination chambers (3, 4, 5, 6), and the decontamination device (1) comprising a discharge chamber (12) disposed downstream of the decontamination chambers (3, 4, 5, 6) and having a discharge opening (2)

Abstract: An apparatus for sterilizing post-consumer absorbent sanitary products, comprising: a container rotatable about a longitudinal axis, having a closed first end and a second end provided with an opening for loading/unloading, closed by a removable door, wherein the container has a hollow wall including an inner wall, an outer wall, and a hollow space, which extends from said first end to said second end, a rotary joint located at said first end of the container and having a steam inlet chamber and a condensate discharge chamber, at least one hollow helical blade, which extends between said first end and said second end of the container and protrudes inwardly from said inner wall of the container.

Abstract: A method for controlling an environment within a sterilizer device is disclosed. The method includes equipping an interior space of the sterilizer device with an auxiliary device having a temperature sensor, a humidity sensor, a heating element, monitoring temperature within the sterilizer device, receiving, by the sterilization device, information associated with an initiation of a sterilization cycle of the sterilizer device; monitor duration of the sterilization cycle, receiving, by the sterilization device, information associated with an end of a sterilization cycle of the sterilizer device, determining whether a current humidity measurement is above a predefined threshold, and controlling the heating element to an ON operating state when the current humidity measurement is above the predefined threshold.

Abstract: A sanitization device comprises primary emitters configured to emit sanitizing electro-optical (EO) radiation into an interior compartment. A support member is configured to hold and/or secure a target object within the interior compartment of a sanitization device. An end portion of the support member may extend into a secondary compartment comprising a secondary emitter configured to produce external stimulus adapted to excite and recover primary emitters from dormancy. The support member is configured to transmit EO radiation produced by the secondary emitter into the interior compartment to thereby prevent and/or recover from dormancy conditions of the primary emitters. Detection circuitry can detect activation failures of the primary emitters. Thermal management circuitry can limit certain critical failures of a sanitization device that result from activation failures of primary emitters.

Abstract: A system for monitoring performance of a water sanitation device includes a housing having a water flow path, a power source, an ozone generating element configured to provide ozone to the water flow path, and an ultraviolet (UV) light generating element configured to expose the water in the flow path to UV light, a first monitoring circuit configured to monitor at least one operational aspect of the ultraviolet (UV) light generating element, a second monitoring circuit configured to monitor at least one operational aspect of the ozone generating element, a control circuit configured to receive an output of the first monitoring circuit and an output of the second monitoring circuit, and a display element configured to provide an indication of a status of at least one of the power source, the ultraviolet (UV) light generating element and the ozone generating element.

Abstract: An ultraviolet (UV) light sanitizing system and method are configured to sanitize at least one surface within an enclosed space. The UV light sanitizing system includes a UV light assembly that is selectively moveable between a stowed position and a deployed position. The UV light assembly is stowed within a stowage chamber connected to the enclosed space in the stowed position. The UV light assembly deploys out of the stowage chamber and into the enclosed space in the deployed position.

Abstract: A connector is configured to electrically connect a plasma emitter array with an identification chip to a power supply controller, and to further mechanically support the emitter device supporting the array during use. Cooperating components of the connector and emitter device form a magnetic latch assembly: the connector includes one or more magnets flush with a top receiving surface of the connector, and one or more alignment pegs extending outward from the receiving surface; the emitter device includes a steel plate attached to a substrate, and one or more holes disposed through the plate and the substrate. The holes align with the alignment pegs and the magnets attract the plate and secure the emitter device against the top receiving surface. Electrical contacts of the connector establish electrical communication with the identification chip, providing power to the emitter device and enabling the controller to read data stored in the identification chip.

Abstract: A system for disinfecting an enclosed area may include a humidity sensor, and a fogging device including a portable housing, an atomizing disinfectant generator carried by the portable housing, at least one output circuit carried by the portable housing, and a processor carried by the portable housing. The processor may be configured to determine a humidity level within the enclosed area based upon the humidity sensor, operate a humidity control device via the at least one output circuit responsive to the determined humidity control level being outside of a starting humidity range, cease operating the humidity control device responsive to the humidity level being within the starting humidity range based upon the humidity sensor, and initiate a treatment cycle during which the atomizing disinfectant generator dispenses atomized disinfectant fluid into the enclosed area.

Abstract: Disclosed is a method and apparatus for providing polyiodide resin-enhanced personal protective equipment (PPE) including but not limited to face masks, gloves, gowns and respirators. The disclosed method comprises the application of a polyiodinated ink polymer in or on one or more targeted surfaces of PPE to create a molecular sub-microscopic protective barrier between the equipment and the user. The disclosed system provides a PPE device capable of direct contact kill of organisms. In addition, the system provides for a sustained kill of organisms for up to 96 hours. The resultant PPE device is broadly effective against viral, bacterial, fungicidal and other microbial agents.

Abstract: An apparatus for use in a method of decontaminating a device including a tray. A membrane permeable by a decontaminating fluid is positioned over the top of the tray to form an enclosed space. A lid is secured to the tray and the membrane is positioned between the tray and the lid. A hub assembly is positioned within the tray.

Abstract: The present invention discloses an automatic source-seeking indoor pollution purifying and removing device and method for airborne pollutants. The device comprises pollutant concentration sensors, a control unit, a position sensor, a power plant, a moving mechanism, a telescopic device, a pollutant collection hood, and a filtering and purifying device. The control unit can identify the actual release positions and hourly release rates of relevant pollutants according to the concentration data monitored by the pollutant concentration sensors, and can control the pollutant collection hood in the device to move to a designated position in a space, so as to realize the collection and removal of pollutants at the release position of the pollutants.

Abstract: An air freshening device is provided. The device includes a water-based fragrance emitter including water, a water absorbing polymer and a fragrance composition. The fragrance composition includes from about 3% to about 70% by weight of at least one fragrance ingredient exhibiting a standard equilibrium headspace concentration (HSi0) below about 100 ?g/L. The water-based fragrance emitter provides a working signal and an end of life signal upon evaporation. The air freshening device is a warming device.

Abstract: An aroma diffuser structure includes a base, a holding member, a frame, an adjusting member, and an aroma diffuser. The holding member is mounted on the base and has a screw hole. The frame is mounted on the holding member and has an upper portion provided with a first magnetic member. The adjusting member has an external threaded section extending through the frame and screwed through the screw hole of the holding member. The aroma diffuser has a plurality of air vents. The aroma diffuser is rotatable on the adjusting member and has a top provided with a rotation shaft which is provided with a second magnetic member magnetically attracted with the first magnetic member.

Abstract: A nebulizer diffuser comprises a base, a nebulizer module, a power supply unit, at least one fluid container module, and a cover. The base comprises a conducting chamber comprising a first through hole, wherein the conducting chamber is for holding a first fluid; an accommodation space, wherein the conducting chamber is located above the accommodation space. The nebulizer module comprises an oscillator and a controller which manages the operation of the oscillator, wherein the oscillator is attached to the first through hole and the controller is disposed in the accommodation space. The power supply unit is disposed in the accommodation space and electrically connected to the nebulizer module. The at least one fluid container module comprises a fluid tank separably located on the conducting chamber and the fluid tank is for holding a second fluid. The cover separably covers on the fluid tank and an air chamber is formed thereinside.

Abstract: An aroma cartridge 100 includes a columnar housing 360 consisting of upper and lower surfaces 362 and 364 parallel to and congruent with each other, and a side surface 366 formed to connect their circumferences. Housing 360 has a hollow portion in which a scent source is sealed. In the housing 360, an air feed inlet 220 communicating with the hollow portion and the outside of the housing, and a scent passage 300 are formed. The aroma cartridge 100 further includes a metal plate 240 of ferromagnetic body, fixed at least on a portion of the side surface 366. By providing a magnet on a cartridge loading section of the aroma cartridge, aroma display can be loaded/unloaded with aroma cartridge 100 easily and reliably.

Abstract: An antiviral air-filtering lighting device includes an air-permeable lampshade, a visible light source, a driver, and an air circulation mechanism. The lampshade diffuses a visible light emitted from the visible light source and includes an air inlet port. The lampshade is coated with a visible-light activatable antiviral photocatalytic coating. The visible light source is disposed inside the lampshade to shine its light through the lampshade to activate the visible-light activatable antiviral photocatalytic coating on the lampshade. The air circulation mechanism sucks an ambient air from outside the lighting device, and forces the air through the lampshade. The lampshade traps airborne microbials on the surface having the visible-light activatable antiviral photocatalytic coating.

Abstract: Provided is a discharge device that can improve the efficiency of generating reactive species. A discharging unit that discharges in response to an application of a voltage protrudes from a housing. The discharging unit is disposed in a duct through which gas flows. An upstream support is disposed upstream of the discharging unit in a direction of gas flow without overlapping the discharging unit. The upstream support protrudes further from the housing than the discharging unit. The upstream support includes a root portion joined to the housing. The root portion includes a widened portion that is disposed in the duct and that protrudes toward the discharging unit when viewed in the direction of gas flow.

Abstract: A negative ion generator includes a fiber bundle, a boost circuit board, a sleeve component and an electrically conductive adhesive. The fiber bundle includes a combining portion. The boost circuit board is connected to the fiber bundle and includes an electrically conductive terminal. An output end of the electrically conductive terminal is inserted into the combining portion of the fiber bundle. The boost circuit board provides a high-voltage current to the fiber bundle to enable the fiber bundle to emit negative ions by corona discharging. An accommodating space is enclosed by the sleeve component. The combining portion of the fiber bundle is installed inside the accommodating space. The electrically conductive adhesive is poured into the accommodating space and located between the combining portion of the fiber bundle and the output end of the electrically conductive terminal for adhering and electrically connecting the fiber bundle to the electrically conductive terminal.

Abstract: Compositions and methods for sealing tissue of a patient in a wet environment are disclosed.

Abstract: A hemostatic device comprising a biomaterial matrix and a polymeric material prepared by combining the polymeric material with a solvent, applying the combination to the biomaterial, removing the solvent, and retaining an effective layer of the polymeric material to the biomaterial to enhance the performance of the hemostatic device in the treatment of wounds.

Abstract: The invention relates to water-containing hydrogels for dressing wounds, comprising a polyurethane-polyurea copolymer having a polyvalent alcohol, except propylene glycol.

Abstract: An osteostimulative, bioactive and flowable bone void filler or bone cement. This bone void filler may be a settable, hardening material having sufficient compression strength for use in bone repair techniques. The cement may be a calcium phosphate cement having incorporated therein bioactive glass, and can be used as a bone graft substitute or bone void filler for any number of applications in spine surgery and orthopedic surgery, such as for example, subchondral bone repair.

Abstract: A glass structure includes: a plurality of glass particles, each of the glass particles including SiO2, CaO and P2O5; and a bonding portion that bonds the glass particles to one another and contains hydroxyapatite, wherein at least a part of the hydroxyapatite is crystalline in the bonding portion, and wherein a porosity of the glass structure is 15% or less. A method for producing the glass structure includes: preparing a mixture by mixing a plurality of glass particles and an aqueous solution with each other, each of the glass particles including SiO2, CaO and P2O5, and the aqueous solution including calcium and phosphorus and having pH of 4.0 or more; and heating and pressurizing the mixture.

Abstract: A coating for an implant component, in particular a component of a spinal implant, is provided. The coating is a ceramic titanium nitride coating comprising an at % content of 5 to 30 At % of Ag in addition to an at % content of Ti and an at % content of N.

Abstract: The present disclosure features a skin mimetic, including a base layer including a hydrogel; and a top layer including a synthetic stratum corneum. The skin mimetic mimics a skin portion of a human subject, such as a facial skin portion. In an embodiment, the skin mimetic can serve as a mimic for a cheek skin portion, for example, for use in the testing of cosmetic products, therapeutic agents, moisturizers, shaving products, other skin care products, and the like.

Abstract: A bone implant comprising cancellous bone that is essentially free of blood cells, and which has been treated with at least one loosening agent, such as collagenase or a digestive enzyme, for a time and at a concentration to loosen the osteogenic cells in the cancellous bone matrix. The osteogenic cells in the matrix are viable cells. The treatment of the cancellous bone with at least one loosening agent enables the osteogenic cells to be more available for carrying out their osteogenic function and to provide for an increased rate of bone formation. Such implant also may include demineralized bone, such as demineralized cortical bone, which enhances the bone regenerative capacity of the cancellous bone.

Abstract: The present invention provides compositions, systems and methods for treating diabetes in a subject. The composition of the present invention includes a decellularized vascular graft, a biocompatible hydrogel encasement with tunable rigidity, and a plurality of cells such as pancreatic islet cells.

Abstract: Compositions, materials, devices and methods are disclosed for the use of decellularized avian lung scaffolds for potential xenotransplantation and other uses including use as novel lung assist or bridge-to-transplant devices and as potential alternatives to current ECMO devices and technologies. Decellularization of an avian lung and recellularization with human lung cells is described.

Abstract: The present invention provides a surgical implant material for assisted repair of muscle mechanics and a method of preparing the same. The surgical implant material for assisted repair of muscle mechanics comprises a collagen compound within a net-like bacterial cellulose base material. A bacterial cellulose base material is placed into solution of collagen, treated via vortex shaking, dried at room temperature; and then immersed in an aqueous solution of an aldehyde compound under vacuum to react for 10 to 30 minutes, thereby producing the surgical implant material for assisted repair of muscle mechanics. The surgical implant material of the present invention can effectively improve the biocompability, and maintain the flexibility, smoothness and fitness of the base material to reduce the damage to surrounding tissues, thereby reducing the bleeding and inflammatory response.

Abstract: The present invention provides an artificial blood vessel that can achieve a balance between cell penetration efficiency and crush resistance and can regenerate a blood vessel at very high efficiency. Provided is an artificial blood vessel having a tubular shape, including: a foam containing a bioabsorbable material; a reinforcement A containing a bioabsorbable material; and a reinforcement B including threads containing a bioabsorbable material, the foam being reinforced with the reinforcements A and B, wherein the reinforcement A is a non-woven fabric, a film, or a weft-knitted, warp-knitted, or woven fabric made of knitted or woven fibers, the reinforcement B includes monofilament threads each having a cross-sectional diameter of 0.

Abstract: A textile graft includes a tubular wall disposed between a first open end and an opposed second open end and having an inner surface and an opposed outer surface. The tubular wall includes a textile construction of one or more filaments or yarns, the textile construction by itself being permeable to liquid. A portion of the inner surface of the tubular wall includes a coating of a substantially water-soluble material thereon. The outer surface includes a coating of a substantially water-insoluble elastomeric sealant disposed thereon. The tubular wall having the coating of the substantially water-insoluble elastomeric sealant is, after curing thereof, substantially impermeable to liquid.